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(-40.2%, p = 0.0007) and fewer physician visits (-4.4%,
p = 0.0259), than those on SAL/FLU, after controlling for base-
line characteristics. The BUD/FORM patients were less likely to
switch to an alternative ICS + LABA combination (OR = 0.58,
p = 0.0067). Numbers of hospitalisations, referrals and work
absences did not differ between groups. CONCLUSION: BUD/
FORM was associated with a lower probability of treatment
switches, fewer acute exacerbations, and with similar or lower
resource utilisation compared with SAL/FLU. Although the
groups appeared well matched at treatment initiation, these
results should be interpreted with caution given the observational
nature of this study.
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PHYSICIAN ADHERENCETO NATIONAL ASTHMA
PRESCRIBING GUIDELINES: EVIDENCE FROM U.S.
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OBJECTIVES: EPR-2 guidelines were developed to improve
medication prescribing for patients with persistent asthma and to
control acute exacerbations of asthma. In addition these guide-
lines also encourage physician provided asthma education. Little
is known about prescribing adherence to EPR-2 guidelines. This
study examined physician adherence to EPR-2 asthma medica-
tion prescribing guidelines and determine patient and physician
factors associated with prescribing of asthma medications.
METHODS: This study was a cross-sectional retrospective
analysis of complex NAMCS physician visit survey data from
1998 through 2004. Data were extracted on all patient s with an
ICD-9 code for asthma (493.XX) and reason for visit as
‘asthma’. Unit of analysis was individual patient visit. Dependent
variables in analyses were speciﬁc type of drug class. Independent
variables were various patient and physician factors. Logis-
tic regression analysis was used to assess study objectives.
RESULTS: Asthma patients in 2002 were 3.3 times more likely to
be prescribed controller medications compared in 1998. Findings
in 2004 were not signiﬁcant. Elderly patients were 54% as likely
to receive controller medication compared to the 35–64 year age
group. Patients other than whites or African Americans are 40%
as likely to receive controller asthma medication compared
to whites. Physicians were 6.3 times more likely to prescribe
long acting beta agonists compared to 1998. Physicians without
ownership stake in their practice were 1.9 times more likely to
provide asthma education to their patients compared to those
who owned their practice. CONCLUSION: This study using US
outpatient setting data provides evidence that physician prescrib-
ing of asthma pharmacotherapy in the US does not adequately
comply with EPR-2 treatment guidelines.
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USING CLAIMS DATATO MODELTHE BUDGETARY IMPACT
OF A NEWTREATMENT FOR RHINITIS
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OBJECTIVES: Medical care costs for rhinitis are primarily
driven by patient care-seeking behavior and physician prescrib-
ing patterns, which may evolve over time. Estimating a model of
real-world rhinitis treatment from clinical trial data is not fea-
sible due to short trial durations and protocol-driven care. There-
fore, we used U.S. health care claims data to model rhinitis
treatment patterns and estimate the budgetary impact of a novel
rhinitis therapy. METHODS: We developed a three-year budget-
ary impact model of rhinitis using Markov-modeling techniques.
Transitions between treatment regimens (monotherapy, dual-
combination therapy, tri-combination therapy), treatment pat-
terns, (therapy switching, add-on rates), and associated medical-
care costs, were estimated from a large claims database, by
identifying rhinitis patients and tracking changes in therapy over
time. Budgetary impact of a novel treatment was assessed for
three effectiveness scenarios, where the switching/add-on rates
relative to ﬂuticasone propionate, an existing rhinitis therapy,
were 50% lower (Scenario 1), 25% lower (Scenario 2) and
identical (Scenario 3). The novel treatment was assumed to be
priced the same as ﬂuticasone propionate and have a market
share of 10%. RESULTS: The claims analysis found annual rates
of treatment switching, add-on, and remaining on initial therapy
ranging from 6–18%, 20–28%, and 62–72%, respectively,
for currently existing rhinitis therapies. Annual rhinitis-related
medical costs associated with each treatment pattern were $666,
$657, and $558, respectively. In Scenario 1, the model predicted
the per-patient-per-month (PPPM) budgetary impact for the
novel treatment to be -$0.06, -$0.09, and -$0.11, in years 1–3,
respectively. Scenarios 2 and 3 had corresponding PPPM results
of $0.00, -$0.01, and -$0.01, and $0.05, $0.06, $0.08. CON-
CLUSION: Using claims data and Markov-modeling techniques,
we found that budgetary impact can be materially affected by
rates of treatment switching/add-on. Detailed, claims-based data
are required for this type of analysis, given the real-world nature
of treatment patterns and associated medical costs.
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OBJECTIVES: We hypothesized that the average medication
possession ratio (MPR) for controller medications in adult asth-
matic populations may be misleading as a basis for evaluating
adherence. METHODS: MPR distributions were determined
from analysis of the Pharmetrics database for the period April
2004 to March 2005. We assessed MPRs for those plan members
exclusively on one of the three major controller medication
groups: inhaled corticosteroids, combined inhaled corticoster-
oids and long acting beta agonists, and leukotriene modiﬁers.
MPR were deﬁned in terms of annual days supplied (range 0 to
1.0). RESULTS: Overall, for the study population (n = 17,581)
5,806 were exclusively on combination therapy (33.8%), 2,689
were exclusively on leukotriene modiﬁers (15.3%) and 2,106
exclusively on inhaled corticosteroids (12.0%). Average (median)
MPRs were 0.51 (0.57) for combination therapy; 0.55 (0.63) for
leukotriene modiﬁers; and 0.39 (0.33) for inhaled corticoster-
oids. Distributions of MPRs for these groups showed signiﬁcant
bi-modality (a “U” shaped MPR proﬁle). This characteristic was
most pronounced for the combined controller group medications
and the leukotriene modiﬁers where the frequency distributions
were almost identical. For the combined medications 32.2% of
adults reported a MPR < 0.2, with 19.0% and 28.9% reporting
MPRs of 0.6 to 0.79 and 0.8 to 1.0 respectively. The correspond-
ing estimates for leukotriene modiﬁers were 27.5%, 19.6%
and 33.1% respectively. For inhaled corticosteroids, 45.2% of
patients reported an MPR < 0.2 with only 33.2% reporting an
MPR > 0.6 (15.5% > 0.8). CONCLUSION: This analysis con-
ﬁrms the hypothesis that average MPR may be a misleading
indicator of adherence in patients taking combined controller
medications and leukotriene modiﬁers. We suggest an approach
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that takes explicit account of the underlying MPR distribution to
understand better the nature of asthma controller medication
possession.
ALLERGY/ASTHMA—Methods and Concepts
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PHARMACOECONOMIC ANALYSIS OF A NEW CONCEPT FOR
SYMBICORT USE IN BRONCHIAL ASTHMA PATIENTS
Arkhipov VV, Chapurin S, Churilin Y
Sechenov Moscow Medical Academy, Moscow, Russia
OBJECTIVES: Pharmacoeconomics analysis of SMART
(Symbicort Maintenance and Reliever Therapy) in compare to
treatment with Seretide Multidisc and to routine therapy of
BA in Russia. METHODS: An incremental cost-effectiveness
analysis of three scenarios for BA drug therapy was done: 1)
SMART (Symbicort (Budesonide/Formoterol) 320/9 or 640/18
ìg/day + Symbicort 160/4,5 ìg/day as needed); 2) Seretide
((Fluticasone/Salmeterol) treatment (from 200/100 ìg/day to
1000/100 ìg/day) in combination with Salbutamol as needed; and
3) Routine BA therapy Comparison of SMART vs Seretide treat-
ment was based on the results of COSMOS study—randomized
study, 2143 patients with BA from 16 countries, follow-up
period 52 weeks. Routine practice was based on the results of
local pharmacoepidemiological study of outpatient treatment,
1362 patients from 20 RF regions. The study gathered informa-
tion of the type of drug therapy, health care system (HC)
resources for 1 year. Values of following ICER were compared: 1)
Difference between costs of HC resources per one additionally
invested ruble, required for a given treatment scenario 1 or 2
vs routine therapy: {HC costs (scenario) - HC costs (routine
therapy)}/{DT cost (scenario) - DT cost (routine therapy)}
DT - Drug Therapy, and 2)Difference between BA burden per
one additionally invested ruble, required for a given treatment
scenario 1 or 2 vs routine therapy: {BA burden (scenario) - BA
burden (routine therapy)}/{DT cost (scenario) - DT cost (routine
therapy)} RESULTS: Switching of patients from routine treat-
ment to SMART would reach the reduction of BA burden by 57
thousand rubles/pt/year depending on length of hospitalization
and in some regions it could be 78,000 rubles/pt/year. CONCLU-
SION: SMART in BA treatment is more preferable compared to
the routine therapy and treatment by Seretide.
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OBJECTIVES: Previous economic comparisons of montelukast
(MON) and salmeterol (SAL) used in GINA step 3 (add-on to
inhaled corticosteroids) disregard QALY measures, side-effect
costing and real-world compliance. A cost-utility model was
developed with locally imputable cost data (of drugs, asthma
attacks, and side effects, covered by the insurer). METHODS: A
large 48-week (N = 1490) randomized, double-blind trial com-
paring MON and SAL. EQ-5D quotients were derived from
AQLQ results using a multivariate model developed at ScHARR
(Shefﬁeld, UK). ANCOVA was used to calculate changes adjusted
for baseline EQ-5D. Asthma exacerbations were costed by
deﬁned categories. A side-effect model restricted to oral infec-
tions and cardiovascular events (further grouped into two and six
homogeneous cost categories, respectively) was constructed to
approximate costing of all drug-related clinical adverse experi-
ences. Adjustments of exacerbation risks and drug costs with the
relative compliance [SAL versus MON: 0.8 (range 0.5–0.9)] were
allowed to convert trial results to the real world observations.
The model was tested with costs covered by the Hungarian and
Swedish national insurance agencies. RESULTS: Among patients
with a baseline and at least one post-baseline AQLQ measure-
ment (n = 1162), there was an average increase in EQ-5D [least-
squares mean (SE)] of 0.080 (0.0054) and 0.081 (0.0054) with
MON and SAL, respectively, resulting an approximate gain of
0.056 (SE 0.0041) QALYs per patient in each group, assuming
equal compliance, over the 48 weeks. There was numerically less
exacerbations but more asthma-related hospitalizations with
SAL, and more costed side-effects (7.9% vs. 5.2%; RR = 1.52,
95% CI 1.03–2.25) compared to MON. The increased costs of
asthma attacks and side-effects with SAL were offset by the
treatment costs with MON. CONCLUSION: If efﬁcacy and costs
are adjusted for the real-world compliance, MON provides a
greater QALY-gain at an increased overall cost compared to SAL
in asthma patients inadequately controlled with inhaled corticos-
teroids alone.
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STATETRANSITION MODELS FOR ESTIMATINGTRANSITION
PROBABILITIES IN MARKOV MODELS
Campbell JD, Blough DK, Sullivan SD
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OBJECTIVES: We explore the use of state transition models
for estimating health state transition probabilities in a Markov
model. Using this approach with a longitudinal database, we
assess the Markov chain order and determine whether transition
probabilities depend on other covariates. METHODS: Markov
models rely on the Markovian assumption, i.e. the probability of
transitioning from one state to another is independent of a
patient’s prior history. Transition probabilities can considerably
impact a model’s outputs. We used current guidelines and a
longitudinal adult cohort of asthma patients to characterize their
asthma control every six months into three mutually exclusive
health states not including death: well-controlled, not well-
controlled, and very poorly controlled. We used correlated data
multinomial regression methods to ﬁt state transition models that
included lag covariates for past control status at six-month time
intervals and baseline covariates of interest. We tested the sig-
niﬁcance of ﬁrst-order (six-month lag) and second-order (six and
twelve-month lags) Markov chains and baseline covariates in
predicting six-month transition probabilities. RESULTS: We ana-
lyzed 3488 adults (average follow-up 25 months) with severe or
difﬁcult-to-treat asthma. First and second-order Markov chains,
and baseline severity all signiﬁcantly predicted present control
status (p < 0.0001 respectively). The ﬁrst-order predicted six-
month transition probability from well-controlled to well-
controlled was 0.626 (95% CI = 0.599, 0.653), but second-order
ranged from 0.362 (95% CI = 0.270, 0.467) for those that were
very poorly controlled twelve-months ago to 0.738 (95%
CI = 0.703, 0.770) for those that were well-controlled twelve-
months ago. CONCLUSION: In our example, assuming ﬁrst-
order six-month transition probabilities without regard for a
patient’s second-order (six and twelve-month past) control status
or baseline severity level was a simpliﬁcation that would likely
bias Markov model outputs. All models are simpliﬁcations but
where data are available, state transition models are tools that
can help a Markov model remain simple, but not overly so.
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